Fig. 7

Regional difference in ACM from 3NP+BDNF-treated astrocytes on neuron viability. a Time schedule of ACM collection and treatment. Cortical or striatal astrocytes were treated for 24 h with DMEM (ACM-CTRL), or 3NP 15 mM (ACM-3NP), or 3NP 15 mM and BDNF 50 ng/ml (ACM-3NP + BDNF). Q15 and Q120 cells were treated for 24 h with those ACM. Q15 cells were incubated for 24 h in the presence or absence of ACM from cortical (b) and striatal (c) astrocytes. Q120 cells were incubated for 24 h in the presence or absence of ACM from cortical (d) and striatal (e) astrocytes. Cell viability was evaluated by Trypan blue exclusion assay. Data show mean number of viable cells/ml ± SEM of n = 4 experiments. Differences between all groups were analyzed by one-way ANOVA followed by Bonferroni´s multiple comparison post-test. **p < 0.01, ***p < 0.001 vs. control and ^p < 0.05 vs. ACM-3NP